Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/11/25 23:08:03」(JST)
wiki en
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 胃不全麻痺の治療 treatment of gastroparesis
- 2. 慢性偽性腸閉塞 chronic intestinal pseudo obstruction
- 3. 悪性腫瘍関連胃不全麻痺：病態生理およびマネージメント malignancy associated gastroparesis pathophysiology and management
- 4. 全身性硬化症（強皮症）における消化管疾患の治療 treatment of gastrointestinal disease in systemic sclerosis scleroderma
- 5. 後天性ＱＴ延長症候群 acquired long qt syndrome
English Journal
- High-resolution manometric evaluation of the effects of cisapride and metoclopramide hydrochloride administered orally on lower esophageal sphincter pressure in awake dogs.
- Kempf J1, Lewis F, Reusch CE, Kook PH.Author information 1Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland.AbstractObjective-To evaluate the effects of cisapride and metoclopramide hydrochloride administered orally on the lower esophageal sphincter (LES) resting pressure in awake healthy dogs. Animals-6 adult Beagles. Procedures-Each dog was evaluated after administration of a single dose of cisapride (0.5 mg/kg), metoclopramide (0.5 mg/kg), or placebo (empty gelatin-free capsule) in 3 experiments performed at 3-week intervals. To measure LES pressure, a high-resolution manometry catheter equipped with 40 pressure sensors spaced 10 mm apart was used. For each experiment, LES pressure was recorded during a 20-minute period with a virtual electronic sleeve emulation before treatment (baseline) and at 1, 4, and 7 hours after drug or placebo administration. A linear mixed-effects model was used to test whether the 3 treatments affected LES pressure differently. Results-In the cisapride, metoclopramide, and placebo experiments, median baseline LES pressures were 29.1, 30.5, and 29.0 mm Hg, respectively. For the cisapride, metoclopramide, and placebo treatments, median LES pressures at 1 hour after administration were 44.4, 37.8, and 36.6 mm Hg, respectively; median LES pressures at 4 hours after administration were 50.7, 30.6, and 31.1 mm Hg, respectively; and median LES pressures at 7 hours after administration were 44.3, 28.5, and 33.3 mm Hg, respectively. The LES pressures differed significantly only between the placebo and cisapride treatments. Conclusions and Clinical Relevance-Results suggested that orally administered cisapride may be of benefit in canine patients for which an increase in LES pressure is desirable, whereas orally administered metoclopramide did not affect LES resting pressures in dogs.
- American journal of veterinary research.Am J Vet Res.2014 Apr;75(4):361-6. doi: 10.2460/ajvr.75.4.361.
- Objective-To evaluate the effects of cisapride and metoclopramide hydrochloride administered orally on the lower esophageal sphincter (LES) resting pressure in awake healthy dogs. Animals-6 adult Beagles. Procedures-Each dog was evaluated after administration of a single dose of cisapride (0.5 mg/kg
- PMID 24669921
- Rehabilitating drug-induced long-QT promoters: In-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.
- Durdagi S1, Randall T, Duff HJ, Chamberlin A, Noskov SY.Author information 1Centre for Molecular Simulations and Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada. serdardurdagi@gmail.com.AbstractBACKGROUND: The human ether-a-go-go related gene 1 (hERG1), which codes for a potassium ion channel, is a key element in the cardiac delayed rectified potassium current, IKr, and plays an important role in the normal repolarization of the heart's action potential. Many approved drugs have been withdrawn from the market due to their prolongation of the QT interval. Most of these drugs have high potencies for their principal targets and are often irreplaceable, thus "rehabilitation" studies for decreasing their high hERG1 blocking affinities, while keeping them active at the binding sites of their targets, have been proposed to enable these drugs to re-enter the market.
- BMC pharmacology & toxicology.BMC Pharmacol Toxicol.2014 Mar 8;15(1):14. doi: 10.1186/2050-6511-15-14.
- BACKGROUND: The human ether-a-go-go related gene 1 (hERG1), which codes for a potassium ion channel, is a key element in the cardiac delayed rectified potassium current, IKr, and plays an important role in the normal repolarization of the heart's action potential. Many approved drugs have been withd
- PMID 24606761
- [Some practical questions on chronic stipsis treatment with prucalopride.]
- Bellacosa L1, Cogliandro R, Cremon C, De Giorgio R, Barbara G, Stanghellini V.Author information 1Dipartimento di Scienze Mediche e Chirurgiche Università di Bologna, Bologna, Italia - v.stanghellini@unibo.it.AbstractChronic constipation is a frequent pathological condition bearing relevant socioeconomic burdens, mainly due to uncertain management and unsatisfactory response to traditional laxatives. Prucalopride is a novel enterokinetic drug, that has been demonstrated to improve bowel functions and relieve a broad spectrum of digestive symptoms in patients with severe chronic constipation who had failed to respond to various traditional laxatives. In this paper we discussed the practical aspects of chronic constipation treatment, in particular focusing on some questions about the practical use of prucalopride. Prucalopride is a potent, selective, high-affinity agonist of the 5-HT4 receptors widely expressed in the gastrointestinal tract. Unlike other 5-HT4 agonists, such as cisapride and tegaserod, it is devoid of adverse cardiovascular effects. Furthermore, it is characterized by a low potential for interactions with other drugs, due to its pharmacokinetic characteristics. Prucalopride was approved, in 2009, by the European Medicines Agency for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief, however, there are ongoing studies to extend the use of the drug even to males.
- Minerva gastroenterologica e dietologica.Minerva Gastroenterol Dietol.2014 Mar;60(1):85-99.
- Chronic constipation is a frequent pathological condition bearing relevant socioeconomic burdens, mainly due to uncertain management and unsatisfactory response to traditional laxatives. Prucalopride is a novel enterokinetic drug, that has been demonstrated to improve bowel functions and relieve a b
- PMID 24632771
Japanese Journal
- A mechanism for the proarrhythmic effects of cisapride (Propulsid) : high affinity blockade of the human cardiac potassium channel HERG
- RAMPE D
- FEBS Lett. 417, 28-32, 1997
- NAID 80009963394
Related Links
- FDA Approves a New Silicone Gel-filled Breast Implant » "The U.S. Food and Drug Administration today approved the MemoryShape Breast Implant to increase breast size (augmentation) for use in women at least 22 years old and to ...
- My allergist has suggested that I double my Propulsid dosage to 20 mg 4 times a day for several weeks. If at the end of that period I am not any better, he will refer me back to the gastroenterologist... ... This is a place to ask ...
Related Pictures
★リンクテーブル★
| リンク元 | 「シサプリド」 |
「シサプリド」
- 副作用により販売停止となっている
- CYP3A4で代謝を受けるために、これを阻害する薬物との併用でQT延長を引き起こしうる